The biosimilar landscape is growing, but the FDA should leverage analytical data to efficiently determine the quality of these products and propel them toward approval, according to a session at the Academy of Managed Care Pharmacy’s Nexus 2023 conference.While the FDA continues to have high standards of approval for biosimilars, the agency is concentrating efforts […]
